Daniela Begolo

Daniela Begolo is a Managing Director at EQT Life Sciences, where she focuses on biotech investments in therapeutics and enabling technologies. Her work spans the full investment lifecycle from sourcing through board engagement and value creation. Based in Amsterdam and Munich, Daniela contributes to EQT's biotech investment strategy across Europe, working closely with the global Life Sciences team on global opportunities. Daniela joined EQT in 2023 and serves on the boards of SpliceBio, Kinaset Therapeutics, and Mosanna Therapeutics. Daniela holds an MSc and BSc in Biotechnology from University of Padova and a PhD in Molecular Biology from University of Heidelberg, earned as part of the Marie Curie Actions program. Prior to joining EQT, she was a Principal at Inkef in Amsterdam, focusing on biotech, medtech, and digital health investments, and worked as an Analyst at M Ventures, the corporate venture capital arm of Merck KGaA. She also conducted academic research at the Center for Molecular Biology (ZMBH) at Heidelberg University.